## STATEMENT OF ACTING CHAIRMAN MICHAEL J. COPPS

RE: Investigation of the Spectrum Requirements for Advanced Medical Technologies, ET Docket No. 06-135; Amendment of Parts 2 and 95 of the Commission's Rules to Establish the Medical Device Radiocommunication Service at 401-402 and 405-406 MHz, RM-11271; DexCom, Inc., Request for Waiver of the Frequency Monitoring Requirements of the Medical Implant Communications Service Rules, ET Docket No. 05-213; Biotronik, Inc., Request for Waiver of the Frequency Monitoring Requirements of the Medical Implant Communications Service Rules, ET Docket No. 03-92

Few uses of our spectrum could be more important than supporting new medical technologies that can extend and improve lives. Our nation's medical researchers continue to develop extraordinary body-worn and implanted devices that are used to treat a variety of health conditions with less invasive patient treatment options. Today's order takes us another major step forward with the establishment of a new Medical Device Radiocommunication Service, which incorporates the existing Medical Implant Communications Service band with additional spectrum for advanced wireless medical radiocommunication devices used for diagnostic and therapeutic purposes. Among other things, these devices are used to control heart rhythms to prevent attacks, mitigate the tremors of neurological patients, and control the delivery of insulin to patients with diabetes.

I am always pleased to support these kinds of achievements. Once again I thank our Office of Engineering and Technology, working in conjunction with the National Telecommunications and Information Administration (NTIA), for developing these new rules.